Reaction products were diluted five times upon addition of 10 mmol l−1 Tris-HCl (pH 8.3) buffer. Adapters were produced by mixing equimolar amounts of complementary oligonucleotides (Eurogentec, Seraing, Belgium): (5′-CTCGTAGACTGCGTACC-3′ and 5′-CGGGTACGCAGTC-3′ for HpyCH4IV; 5′-GACGATGAGTCCTGAC-3′ and 5′-TAGTCAGGACTCAT-3′ for MseI) and heating the mixture to 95 °C followed by slow cooling to ambient temperature. One microlitre of the diluted restriction-ligation mixture was used for amplification in a reaction volume of 25 μl containing

1 μmol l−1 Alvelestat solubility dmso M HpyCH4IV primer with one selective residue (underlined) (5′-Flu-GTAGACTGCGTACCCGTT-3′), 1 μmol l−1 MseI primer with four selective residues (underlined) (5′-GATGAGTCCTGACTAATGAA-3′), 0.2 mmol l−1 of each deoxynucleoside triphosphate, PF-02341066 concentration and 1 U of Taq DNA polymerase (Roche Diagnostics) in 1× reaction buffer containing 1.5 mmol l−1 MgCl2. Amplification was performed as follows. After an initial denaturation step at 94 °C for 4 min in the first 20 cycles, a touchdown procedure was applied: 15 s denaturation at 94 °C; 15 s annealing at 66 °C with the temperature for each successive cycle lowered by 0.5 °C and 1 min

of extension at 72 °C. Cycling was then continued for further 30 cycles with an annealing temperature of 56 °C. After completion of the cycles, incubation at 72 °C for 10 min was included before the reactions were cooled to room temperature. Products were diluted 1 : 10 with distilled water. To 1 μl of diluted product, 0.25 μl of ET400-R size marker (GE Healthcare, Osimertinib clinical trial Diegem, Belgium) and 8.75 μl of distilled water were added. Following 1-min denaturation step at 94 °C, the samples were

quickly cooled to room temperature and analysed on a MegaBACE 500 automated DNA analysis platform equipped with a 48-capillary array according to the instructions of the manufacturer (GE Healthcare). AFLP data were imported into BioNumerics v. 6.0 Software (Applied Maths, Sint-Martens-Latem, Belgium) and analysed by UPGMA clustering using the Pearson correlation coefficient. The analysis was restricted to DNA fragments in the range from 60 to 300 bp. Clinical isolates were identified to the species level based on the similarity of their AFLP profile to those of the type strains. To assign specific AFLP genotypes, the obtained profiles were also inspected visually and scored for presence/absence of clearly recognisable DNA fragments. Two profiles differing by at least one clearly recognisable DNA band were considered to represent different genotypes.